Living with AFib: Treatment Options Explained

Atrial fibrillation — AFib — is the most common sustained cardiac arrhythmia, affecting an estimated 6 to 12 million Americans. If you have been diagnosed with AFib, you may have felt the palpitations, the breathlessness, the unsettling awareness of your own heartbeat. You may also have felt overwhelmed by the treatment conversation, which involves medications with serious names, electrical cardioversions, and procedures you have never heard of before. This guide is designed to demystify all of it — giving you a clear map of every evidence-based AFib treatment option so you can have an informed conversation with your cardiologist. ## Understanding What AFib Is Doing to Your Heart In a normal heart, the electrical signal originates in the sinoatrial node and travels in an orderly path that produces a rhythmic, coordinated beat. In AFib, the upper chambers (atria) fire chaotically — often 400 to 600 times per minute — causing disorganized, quivering contractions instead of effective pumping. Two consequences matter most clinically: **Hemodynamic impairment.** The atria lose their coordinated contraction, reducing the heart's filling efficiency by 20 to 30 percent. This explains why many AFib patients feel fatigued, short of breath, or unable to tolerate exercise they previously managed without difficulty. **Stroke risk.** Blood pooling in the left atrial appendage — a small pouch in the left atrium — can clot. If that clot embolizes, it travels to the brain, causing a stroke. AFib is responsible for approximately 15 to 20 percent of all strokes and produces strokes that are on average more disabling than strokes from other causes. Treatment strategy addresses both of these problems. ## Stroke Prevention: Anticoagulation For most patients with AFib, anticoagulation (blood thinners) is the foundational treatment regardless of whether rhythm or rate is being managed. Your cardiologist will calculate your stroke risk using a scoring system called CHA₂DS₂-VASc, which assigns points for age, sex, heart failure, hypertension, diabetes, prior stroke, and vascular disease. Patients with a score of 2 or higher (1 or higher in women) typically benefit from anticoagulation. **Direct oral anticoagulants (DOACs)** — apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) — are now preferred over warfarin (Coumadin) for most patients. DOACs require no routine blood monitoring, have fewer drug and food interactions, and have similar or better safety profiles compared to warfarin in clinical trials. Warfarin remains appropriate for certain patients, particularly those with mechanical heart valves or severe kidney disease. It requires regular INR monitoring to keep the blood-thinning level in a therapeutic range. For patients who cannot tolerate anticoagulants, the WATCHMAN device offers an alternative — a small plug implanted in the left atrial appendage to prevent clots from escaping. It is an option for patients with high stroke risk and high bleeding risk. ## Rate Control: Letting the Rhythm Stay, Slowing the Ventricular Response In many patients — particularly older patients with few symptoms — the goal is not to restore normal sinus rhythm but to slow the ventricular rate so the heart is not beating 100 to 150 times per minute at rest. This approach, called rate control, reduces symptoms and protects the heart from tachycardia-induced cardiomyopathy (heart weakening from prolonged rapid rate). Medications used for rate control include: - **Beta-blockers** (metoprolol, carvedilol) — slow the heart rate and are the first choice for most patients, including those with heart failure with reduced ejection fraction - **Calcium channel blockers** (diltiazem, verapamil) — effective rate control in patients without significant systolic dysfunction - **Digoxin** — less effective for active patients whose rate increases with exertion; used as an adjunct in some heart failure patients For patients who cannot achieve adequate rate control with medications, atrioventricular (AV) node ablation combined with pacemaker implantation eliminates the rapid ventricular conduction and provides a controlled, paced rate. ## Rhythm Control: Restoring and Maintaining Normal Sinus Rhythm Increasingly, evidence supports a rhythm control strategy — particularly in patients who are symptomatic, younger, or earlier in their AFib course. The EAST-AFNET 4 trial demonstrated that early rhythm control significantly reduced cardiovascular outcomes compared to rate control alone. Rhythm control can be achieved in two ways: ### Cardioversion Electrical cardioversion delivers a synchronized shock to reset the heart's rhythm to normal sinus. It works immediately in approximately 90 percent of eligible patients. Cardioversion is effective but does not prevent AFib from returning — most patients experience recurrence within a year without additional therapy. To prevent stroke, patients must be adequately anticoagulated for three to four weeks before cardioversion (or alternatively must undergo a transesophageal echocardiogram to rule out left atrial appendage thrombus) and for at least four weeks afterward, regardless of whether the cardioversion is successful. ### Antiarrhythmic Medications Antiarrhythmic drugs suppress the electrical triggers of AFib to maintain sinus rhythm after cardioversion. Commonly used agents include: - **Flecainide and propafenone** — effective in patients without structural heart disease; "pill-in-the-pocket" regimens are sometimes appropriate for paroxysmal AFib - **Sotalol** — a beta-blocker with antiarrhythmic properties; requires kidney function monitoring and QT interval surveillance - **Amiodarone** — highly effective but carries significant side effects with long-term use, including thyroid and lung toxicity; generally reserved for patients who fail other agents or have severe heart disease - **Dofetilide** — initiated in hospital with continuous cardiac monitoring due to proarrhythmia risk ### Catheter Ablation Catheter ablation has become the most effective rhythm control strategy for patients with paroxysmal or persistent AFib who remain symptomatic despite medication. The procedure involves threading thin catheters through the femoral vein to the left atrium and using radiofrequency energy or cryoablation (freezing) to electrically isolate the pulmonary veins — the most common source of AFib triggers. Pulmonary vein isolation (PVI) achieves freedom from AFib in approximately 70 to 80 percent of patients with paroxysmal AFib after one or two procedures, with symptomatic improvement in the large majority. Success rates are somewhat lower for persistent and long-standing persistent AFib. The CABANA trial and subsequent analyses confirmed that ablation reduces symptoms, AFib burden, and hospitalization compared to drug therapy, and is associated with improved quality of life. Ablation is performed under general anesthesia or deep sedation, typically takes two to four hours, and most patients go home the same day or after one night. Full recovery takes one to two weeks. ## Lifestyle and Risk Factor Management Cardiac risk factor modification is not merely adjunctive — it is essential and, in some patients, powerfully effective on its own. The LEGACY study showed that sustained weight loss of 10 percent or more in obese AFib patients produced a dramatic reduction in AFib burden comparable to ablation. Every AFib management plan should include: - Weight management to a healthy BMI - Blood pressure control to below 130/80 mmHg - Treatment of obstructive sleep apnea (untreated OSA is a major driver of AFib recurrence) - Alcohol reduction or elimination — the dose-response relationship between alcohol and AFib is clear and significant - Regular aerobic exercise (paradoxically, moderate exercise reduces AFib burden; extreme endurance exercise can increase it) ## Which Treatment Is Right for You? Treatment selection depends on your age, symptoms, AFib pattern (paroxysmal, persistent, or long-standing persistent), heart function, comorbidities, stroke risk, and personal preferences. There is no single correct path. Many patients begin with rate control and anticoagulation, then progress to rhythm control if symptoms remain problematic. The important thing is that this is a conversation — not a one-time prescription. Your AFib management will likely evolve over time, and an experienced cardiologist should be re-evaluating your strategy at each visit. *Dr. Michael A. Torres sees patients with atrial fibrillation at Nampa Cardiology Associates. Call (208) 555-0398 to schedule a consultation.*